Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Pharmaceutical
USA-based biopharma firm Paratek Pharmaceuticals has announced positive top-line efficacy data for Nuzyra (omadacycline) as post-exposure prophylaxis (PEP) in a non-human primate (NHP) model of inhalational anthrax. 5 March 2024
Pharmaceutical
Announcing its financial results for 2023, diversified German drugmaker said it would delay a plan to break up the group for at least a couple of years. 5 March 2024
Biotechnology
Californian cardiovascular specialist Bitterroot Bio has entered into a partnership with Biotheus, a Chinese company working on antibodies. 4 March 2024
Pharmaceutical
California’s BridgeBio Pharma and German life sciences company Bayer have announced a collaboration. 4 March 2024
Pharmaceutical
In another legal blow for opponents of the Inflation Reduction Act (IRA), a federal judge has now rejected a bid from AstraZeneca to prevent price negotiations on its diabetes med Farxiga (dapagliflozin). 4 March 2024
Biotechnology
Japanese drugmaker Shionogi has linked up with fellow Osaka-based FunPep Co regarding the anti-IgE antibody-induced peptide FPP004X. 4 March 2024
Biotechnology
California-based Gritstone bio, a biotech company aiming to develop the world’s most potent vaccines, has announced an approximately 40% reduction of its workforce. 4 March 2024
Pharmaceutical
Drugmakers, patient advocate groups, policymakers and others have come together for Rare Disease Day, which took place at the end of February, to both celebrate progress and call for more action in this therapy area. 4 March 2024
Biotechnology
Swiss pharma giant Novartis today presented new data that continue to support the clinical benefits of Zolgensma (onasemnogene abeparvovec), the only one-time gene therapy for the treatment of spinal muscular atrophy (SMA). 4 March 2024
Pharmaceutical
Innovative approaches are poised to revolutionize the treatment of amyotrophic lateral sclerosis (ALS), a challenging and rare disease. 4 March 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze